Utidelone
- Generic Name
- Utidelone
- Drug Type
- Small Molecule
- Background
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.
- Indication
联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。
Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 778
- Registration Number
- NCT06841679
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases
- Conditions
- HER2-negative Breast Cancer Patients with Brain Metastases
- Interventions
- Drug: Utidelone in combination with capecitabine
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Biostar Pharma, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06764940
- Locations
- 🇺🇸
FOMAT Medical Research (Network), Oxnard, California, United States
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticOvarian CancerBile Duct Cancer
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06730581
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
- Conditions
- Non-small Cell Lung Cancer Patients with Brain Metastases
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06683703
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06598046
- Locations
- 🇨🇳
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 143
- Registration Number
- NCT06510465
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
- Conditions
- Breast Cancer Recurrent
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Min Yan, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06458413
- Locations
- 🇨🇳
Henan Cancer hospital, Zhengzhou, Henan, China
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06385990
- Locations
- 🇨🇳
Quchang Ouyang, Changsha, Hunan, China
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
- Conditions
- TNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Huihua Xiong
- Target Recruit Count
- 78
- Registration Number
- NCT06125080
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast Cancer
- Interventions
- Drug: Organoid-guided treatmentDrug: Anthracycline
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.